for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avinger Inc

AVGR.OQ

Latest Trade

1.08USD

Change

0.00(0.00%)

Volume

54,976

Today's Range

1.05

 - 

1.08

52 Week Range

1.05

 - 

15.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.08
Open
1.07
Volume
54,976
3M AVG Volume
9.60
Today's High
1.08
Today's Low
1.05
52 Week High
15.00
52 Week Low
1.05
Shares Out (MIL)
10.23
Market Cap (MIL)
11.05
Forward P/E
-0.64
Dividend (Yield %)
--

Latest Developments

More

Avinger Prices $4.5 Mln Underwritten Public Offering Of Common Stock

Avinger Announces Proposed Underwritten Public Offering Of Common Stock

Avinger Reports Second Quarter Loss Per Share Of $0.87

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Avinger Inc

Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and certain European markets. The Company's products include Lightbox imaging console, as well as its Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris.

Industry

Medical Equipment & Supplies

Contact Info

400 Chesapeake Dr

+1.650.3632400

http://avinger.com/

Executive Leadership

James G. Cullen

Non-Executive Chairman of the Board

Jeffrey M. Soinski

President, Chief Executive Officer, Director

Mark Weinswig

Chief Financial Officer

Himanshu N. Patel

Chief Technology Officer

Jaafer Golzar

Chief Medical Officer

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1,356.000

2017

-720.400

2018

-33.400

2019(E)

-2.000
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.35
Price To Book (MRQ)
0.70
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
82.67
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-199.44
Return on Equity (TTM)
-88.17

Latest News

BRIEF-Avinger Receives FDA Clearance Of Next Generation Pantheris Device

* AVINGER RECEIVES FDA CLEARANCE OF NEXT GENERATION PANTHERIS DEVICE

BRIEF-Avinger Announces First-In-Patient Use Of Extended Nosecone Version Of Next Generation Pantheris

* AVINGER ANNOUNCES FIRST-IN-PATIENT USE OF EXTENDED NOSECONE VERSION OF NEXT GENERATION PANTHERIS Source text for Eikon: Further company coverage:

BRIEF-Avinger To Settle Securities Class Actions For $5 Million

* AVINGER INC - ENTERED INTO BINDING MEMORANDUM OF UNDERSTANDING TO SETTLE SECURITIES CLASS ACTIONS PENDING AGAINST CO, SEVERAL OF OFFICERS & DIRECTORS

BRIEF-Avinger Q4 Loss Per Share $12.58

* AVINGER ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 RESULTS

BRIEF-Avinger Provides Update On U.S. Intellectual Property Portfolio

* AVINGER PROVIDES UPDATE ON U.S. INTELLECTUAL PROPERTY PORTFOLIO

BRIEF-Empery Asset Management LP Reports 9.99 pct Passive Stake In Avinger Inc As Of Feb 14

* EMPERY ASSET MANAGEMENT LP REPORTS 9.99 PERCENT PASSIVE STAKE IN AVINGER INC AS OF FEB 14, 2018 - SEC FILING Source text - http://bit.ly/2sEAury Further company coverage:

BRIEF-Avinger Enteres Into Amendment Of Loan Agreement With CRG Partners

* AVINGER - ON FEB 14, CO ENTERED INTO AMENDMENT NO. 2 TO SEPT. 22, 2015 TERM LOAN AGREEMENT WITH CRG PARTNERS III L.P., CERTAIN AFFILIATED FUNDS

BRIEF-Avinger Says Signed Waiver Agreement With CRG Partners III And Certain Of Its Affiliated Funds, As Lenders​

* AVINGER SAYS ON JAN 24, ENTERED INTO WAIVER AGREEMENT WITH CRG PARTNERS III L.P. & CERTAIN OF ITS AFFILIATED FUNDS, AS LENDERS - SEC FILING

BRIEF-Avinger Announces Reverse Stock Split

* COMPANY WILL EFFECT A 1-FOR-40 REVERSE STOCK SPLIT OF COMPANY'S COMMON STOCK

BRIEF-Avinger Inc Files For Common Stock Offering Of Up To $15 Mln

* AVINGER INC FILES FOR COMMON STOCK OFFERING OF UP TO $15.0 MILLION - SEC FILING Source text (http://bit.ly/2r1hfbc) Further company coverage:

BRIEF-Avinger Receives CE Marking Approval For Next Generation Pantheris Image-Guided Atherectomy Device

* AVINGER RECEIVES CE MARKING APPROVAL FOR NEXT GENERATION PANTHERIS IMAGE-GUIDED ATHERECTOMY DEVICE Source text for Eikon: Further company coverage:

BRIEF-Avinger Secures Waiver And Consent To CRG Loan Agreement

* AVINGER SECURES WAIVER AND CONSENT TO CRG LOAN AGREEMENT Source text for Eikon: Further company coverage:

BRIEF-Avinger Says Executive Chairman John Simpson Will Be Leaving Company

* AVINGER INC - JOHN B. SIMPSON, FOUNDER AND EXECUTIVE CHAIRMAN OF AVINGER, WILL BE LEAVING COMPANY

BRIEF-Avinger Q3 loss per share $0.43

* Avinger Inc - cash and cash equivalents totaled $10.2 million as of Sept 30, 2017, compared to $14.0 million as of June 30, 2017 Source text for Eikon: Further company coverage:

BRIEF-Avinger enters common stock purchase agreement for up to $15.0 mln with Lincoln Park Capital

* Avinger enters into common stock purchase agreement for up to $15.0 million with Lincoln Park Capital Source text for Eikon: Further company coverage:

BRIEF-Avinger receives CE marking approval for in-stent restenosis treatment

* Avinger receives CE marking approval for in-stent restenosis treatment indication with pantheris image-guided atherectomy

BRIEF-Avinger Q2 loss per share $0.54

* Q2 revenue fell 47 percent to $2.5 million Source text for Eikon: Further company coverage:

BRIEF-Avinger announces verified data of 24-month outcomes from pivotal vision study of Lumivascular technology

* Avinger announces verified data of 24-month outcomes from the pivotal vision study of Lumivascular technology for Peripheral Artery Disease

BRIEF-Avinger Inc Q1 loss per share $0.64

* Q1 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S

BRIEF-Avinger sees Q1 2017 revenue of about $3.5 mln

* Announced that it has been conducting a review of various strategic alternatives focused on maximizing shareholder value

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up